A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
NCT07470879
This study is recruiting at 7 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to < 12 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Colitis, Ulcerative
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 2 to 11 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Pfizer
- Last updated on ClinicalTrials.gov
- August 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 7
- Fink Children's Ambulatory Care Center · New York, NY
- Kimmel Pavilion - NYU Langone · New York, NY
- NYU Grossman School of Medicine · New York, NY
- NYU Langone Health (Tisch Hospital) · New York, NY
- NYU Langone Inflammatory Bowel Disease Center · New York, NY
- NYU Langone Radiology - Tisch Hospital · New York, NY
- NYU Medical Science Building (MSB) · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.